Client business need
Early access teams at a global pharmaceutical company were responsible for shaping pricing and access strategy for early pipeline assets across multiple therapeutic areas, including oncology and rare diseases. Much of their work focused on Phase 1 and Phase 2 assets, where decisions needed to be made quickly, often with limited clinical data and compressed timelines.
Early pipeline assessments relied on fragmented processes. Teams combined internal expertise with manual research across pricing databases, public HTA assessments, external reports, and, in some cases, consultancy support. Insights were scattered across sources, making it difficult to build a consistent and defensible view of pricing potential, payer expectations, and competitive positioning.
With limited time and resources, Market Access leaders struggled not only to move fast, but to confidently justify their assumptions and recommendations when challenged by R&D, BD, and senior governance forums.
Client goals
The organisation wanted to strengthen its early pipeline market access capability by:
- Accelerating early pricing and access assessments while ensuring assumptions were transparent, defensible, and ready for senior and BD scrutiny
- Rapidly identifying relevant analogues, including for orphan and rare disease assets
- Improving visibility into pricing assumptions, scenarios, and trade-offs
- Gaining earlier insight into likely payer and HTA reactions
- Reducing reliance on external consultancies for routine early-stage analysis
Ultimately, the goal was to enable Market Access teams to influence decisions earlier in the asset lifecycle with credible, evidence-based insights.
Access Infinity response
Access Infinity implemented Nuro as an integrated platform to support early pipeline pricing, access, and HTA strategy.
Nuro enabled teams to rapidly identify and filter relevant analogues based on indication, trial design, regulatory pathway, and approval characteristics. Pricing analysis was fully transparent, allowing users to see and adjust underlying assumptions such as dosing, duration, and population characteristics to model multiple scenarios.
The platform’s AI-powered payer insights supported early Target Product Profile (TPP) evaluation by analysing historical HTA decisions, evidence requirements, and pricing benchmarks. This allowed teams to clearly explain not just price estimates, but the rationale, risks, and trade-offs behind them when engaging with R&D, BD, and governance committees.
In addition, Nuro provided continuously updated HTA intelligence and pipeline competitive insights, ensuring teams worked with current information when shaping early development and access strategy.
Business impact
- Faster turnaround of early pipeline assessments, from days or weeks to hours
- Greater confidence in pricing and access recommendations through transparent, challenge-ready assumptions
- Earlier identification of access risks and opportunities, enabling influence before late-stage development
- Reduced reliance on external consultancies for routine early-stage analysis
- Stronger engagement with R&D and BD teams through clear, defensible strategic insights
Market Access teams shifted from reactive research to proactive strategic leadership earlier in the pipeline.
Find out more
To learn how Nuro helps Market Access teams deliver fast, defensible early pipeline insights, visit the Nuro landing page on our website.
If you would like to see it in action, book a personalised demo to explore how Nuro supports early pricing, access risk assessment, and evidence strategy for pipeline and BD decisions.
